Peter Galle

, Germany

Peter R. Galle, MD, PhD Chairman First Department of Internal Medicine University Medical Center Langenbeckstrasse 1 55131 Mainz Germany Curriculum Vitae Dr. Galle majored in internal medicine at the Universities of Berlin and Marburg/Germany, Hammersmith Hospital, London/UK and University of Texas/USA and received his M.D. degree from Marburg University and Ph.D. degree from Heidelberg University. Initially he held a position as postdoctoral fellow in Molecular Biology at the Centre for Molecular Biology Heidelberg working on the replication of hepatitis B viruses. Afterwards he completed his residency in Internal Medicine and Gastroenterology at the University Hospital of Heidelberg. In 1998 he became Director of the I. Medical Department in Mainz and from 2005 – 2008 he hold the CEO position of Mainz University Hospital. He is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), served as Co-editor for the Journal of Hepatology and is on the Editorial Boards of several other Journals. He served as congress president of the German Society for Digestive Diseases (DGVS) in 2014. He was member of the Executive Board and President of the International Liver Cancer Association (ILCA). He is President of the German association for the Study of the Liver (GASL) 2020 His research has focused on elucidating important aspects of apoptotic cell death in the liver, immune escape of tumour cells and on clinical and molecular aspects of hepatocellular carcinoma. He was awarded several prizes, amongst others the prestigious Tannhauser award, the highest prize of the German Society for Digestive Diseases. He has published more than 500 peer-reviewed papers. Google Scholar Citation Report (AUG 2020) Sum of the Times Cited: 67397 h-index: 115

Chair(s)

Chair - Symposium: Patient prioritization for HCC treatment
Symposium
13 April 2019 14:00 - 15:30 More ...
Chair - Solve the Case: Hepatological challenges
Workshop
14 April 2019 08:30 - 09:30 More ...
Chair - Meet the Experts: Local therapies in HCC
Meet the Experts
11 April 2019 16:00 - 16:50 More ...

Presentations

Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH) 12 April 2019 09:00 - 09:15 More ...

Abstracts

Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH) Liver tumours: Therapy More